approved glp-1 agonists GLP1 receptor agonist @nejm revisión Comparing GLP-type therapies for weight

No significant difference in semaglutide plasma concentration across the four groups was observed and adverse events were similar across groups

It is believed that GLP-1RAs induce vasodilation through action of the proximal tubular cells and stimulating urinary sodium excretion [68, 72]

4 Conclusion The treatment of AD faces serious challenges, and the incidence of this disease is increasing every year, placing a heavy burden on global health

From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection

518,519,520,521 Hepatocellular carcinoma (HCC) Initially developed for treating diabetes, GLP-1RAs have shown potential in treating NASH, which is closely related to HCC

These findings suggest that long-term or intermittent administration of GLP-1RAs is necessary for individuals with obesity to maintain a healthy weight